Risk of colorectal cancer associated with percent genomic leukocyte DNA methylation levels (or %5-mC), the PLCO Cancer Screening Trial, 1993–2001
| Cases (N = 370) | Controls (N = 493) | |||
|---|---|---|---|---|
| %5-mC | n | n | %5-mC cutoff | OR (95% CI) |
| Tertile | ||||
| Third | 104 | 160 | ≥4.11 | 1.00 |
| Second | 146 | 167 | 3.95–<4.11 | 1.44 (1.02–2.03) |
| First | 120 | 166 | <3.95 | 1.14 (0.80–1.63) |
| Ptrend | 0.51 | |||
NOTE: ORs and 95% CIs calculated by unconditional logistic regression adjusted for age, gender, race, time since initial sigmoidoscopy screening, year of randomization, smoking, body mass index, use of NSAIDs, a family history of colorectal cancer, and a prior history of adenoma, hyperplastic polyps, or inflammatory bowel disease or polyposis syndrome (i.e., ulcerative colitis, Crohn disease, Gardner syndrome, and familial polyposis).